Business
Hardman Res.: Funded to the end of Phase II trials
Hardman Res.: Funded to the end of Phase II trials.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 8875Y Evgen Pharma PLC 11 December 2017 \n\nHardman Research: Funded to the end of Phase II trials\nIncreased funding to the end of Phase II trials: Evgen is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen's proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time. SFX-01 is progressing in Phase II clinical trials for both subarachnoid haemorrhage and ER+ breast cancer, with readouts expected in or around the end of 2018. EVG has strengthened its balance sheet with a Placing to raise new funds of £2.3m gross.\nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/11.12.17-funded-to-the-end-of-phase-ii-trials.pdf\n\n\n\n\nTo contact us: \nHardman & Co\n35 New Broad Street\nLondon\nEC2M 1NH\n\n\nAnalysts:\nDr Martin Hall [email protected]\nDr Dorothea Hill [email protected]\nDr Gregoire Pave [email protected]\nTelephone: +44 20 7194 7622\nFollow us on Twitter @HardmanandCo\n\n\n\n\nwww.hardmanandco.com \nAbout Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated ...